Inhibrx Biosciences Inc.
INBX | NASDAQ
$114.92
+$2.88 (+2.57%)
Sep 22, 2026, 10:42 AM ET · Market open
Company Profile
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded by Brendan P. Eckelman on January 8, 2024 and is headquartered in La Jolla, CA.
Key Executives
| Name | Position |
|---|---|
| Mark Paul Lappe | Founder, Chief Executive Officer & Chairman |
| Kelly Devine Deck | Executive Vice President, Chief Financial Officer & Treasurer |
| Ashraf Amanullah | Executive Vice President & Chief Technical Operations Officer |
| Bonne Adams | Vice President of Operations |
| Carlos Bais | EVice President & Chief Scientific Officer |
| David Matly | President |
| Josep Garcia | Executive Vice President & Chief Clinical Development Officer |
| Kate Burke | Vice President of Accounting |
| Leah Pollema | Vice President, General Counsel & Corporate Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 14, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 13, 2026 | 8-K | Current Report |
| Aug 13, 2026 | 10-Q | Quarterly Report |
| Aug 03, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Jul 16, 2026 | 8-K | Current Report |
| Jun 15, 2026 | 8-K | Current Report |
| Jun 04, 2026 | 4 | Filing |
| Jun 04, 2026 | 4 | Filing |
Inhibrx Biosciences Inc.
| Country | United States |
| IPO Date | May 28, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 110 |
| CEO | Mark Lappe |
Contact Details
11025 North Torrey Pines Road La Jolla,
California 92037 United States
Stock Details
| Ticker Symbol | INBX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0002007919 |
| CUSIP Number | 45720N103 |
| ISIN Number | US45720N1037 |
| SIC Code | 2836 |
Recent News
- 6 days ago / fool.comInhibrx Founder and CEO Mark Lappe Buys 25,000 Shares for $2.6 Million. What Does His Confidence Tell Investors?
- 8 days ago / seekingalpha.comInhibrx: 'Strong Buy' Maintained With Ozekibart Action Date On The Horizon And Study Win With INBRX-106
- 13 days ago / seekingalpha.comInhibrx: Market's Lukewarm Response To Yesterday's HNSCC Data Hard To Fathom
- 14 days ago / benzinga.comInhibrx Biosciences Plans Head and Neck Cancer Trial Expansion Following High Response Rates
- 14 days ago / reuters.comInhibrx's combination cancer drug shrinks tumors in mid-stage head and neck cancer study
- 18 days ago / prnewswire.comInhibrx To Host Webcast Presentation to Provide Primary Endpoint Results for INBRX-106 Phase 2 First-Line HNSCC Study
- 1 month ago / prnewswire.comInhibrx Reports Second Quarter 2026 Financial Results
- 2 months ago / prnewswire.comInhibrx Announces Amended Loan Agreement with Oxford Finance, Expanding Total Facility to $500.0 Million
- 3 months ago / zacks.comAre You Looking for a Top Momentum Pick? Why Inhibrx Biosciences, Inc. (INBX) is a Great Choice
- 3 months ago / prnewswire.comInhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma
Add to Watchlist
Select watchlists to add or remove INBX